Alternative Splicing and Tumor Progression

Overview

Journal Curr Genomics

Publisher Bentham Science Publishers

Date 2009 Jun 12

PMID 19516963

Citations 101

Authors

Claudia Ghigna

Cristina Valacca

Giuseppe Biamonti

Affiliations

Soon will be listed here.

Abstract

Alternative splicing is a key molecular mechanism for increasing the functional diversity of the eukaryotic proteomes. A large body of experimental data implicates aberrant splicing in various human diseases, including cancer. Both mutations in cis-acting splicing elements and alterations in the expression and/or activity of splicing regulatory factors drastically affect the splicing profile of many cancer-associated genes. In addition, the splicing profile of several cancer-associated genes is altered in particular types of cancer arguing for a direct role of specific splicing isoforms in tumor progression. Deciphering the mechanisms underlying aberrant splicing in cancer may prove crucial to understand how splicing machinery is controlled and integrated with other cellular processes, in particular transcription and signaling pathways. Moreover, the characterization of splicing deregulation in cancer will lead to a better comprehension of malignant transformation. Cancer-associated alternative splicing variants may be new tools for the diagnosis and classification of cancers and could be the targets for innovative therapeutical interventions based on highly selective splicing correction approaches.

Citing Articles

MAGOH promotes gastric cancer progression via hnRNPA1 expression inhibition-mediated RONΔ160/PI3K/AKT signaling pathway activation.

Yu S, Chen C, Chen M, Liang J, Jiang K, Lou B J Exp Clin Cancer Res. 2024; 43(1):32.

PMID: 38268030 PMC: 10809607. DOI: 10.1186/s13046-024-02946-8.

Identification of Intron Retention in the Slc16a3 Gene Transcript Encoding the Transporter MCT4 in the Brain of Aged and Alzheimer-Disease Model (APPswePS1dE9) Mice.

El-Seedy A, Pellerin L, Page G, Ladeveze V Genes (Basel). 2023; 14(10).

PMID: 37895298 PMC: 10606527. DOI: 10.3390/genes14101949.

Novel thrombospondin-1 transcript exhibits distinctive expression and activity in thyroid tumorigenesis.

Hong Y, Kim I, Moon H, Lee J, Lertpatipanpong P, Ryu C Oncogene. 2023; 42(22):1832-1842.

PMID: 37055552 DOI: 10.1038/s41388-023-02692-9.

Investigation of androgen receptor-dependent alternative splicing has identified a unique subtype of lethal prostate cancer.

Seltzer S, Giannopoulos P, Bismar T, Trifiro M, Paliouras M Asian J Androl. 2022; 25(3):296-308.

PMID: 36259569 PMC: 10226513. DOI: 10.4103/aja202263.

SERBP1 affects the apoptotic level by regulating the expression and alternative splicing of cellular and metabolic process genes in HeLa cells.

Zhou J, Chen W, He Q, Chen D, Li C, Jiang C PeerJ. 2022; 10:e14084.

PMID: 36213507 PMC: 9536300. DOI: 10.7717/peerj.14084.

References

Lane T . BRCA1 and transcription. Cancer Biol Ther. 2004; 3(6):528-33. DOI: 10.4161/cbt.3.6.843. View

Thorsen K, Sorensen K, Brems-Eskildsen A, Modin C, Gaustadnes M, Hein A . Alternative splicing in colon, bladder, and prostate cancer identified by exon array analysis. Mol Cell Proteomics. 2008; 7(7):1214-24. DOI: 10.1074/mcp.M700590-MCP200. View

Mazoyer S, Puget N, Lynch H, Lenoir G . A BRCA1 nonsense mutation causes exon skipping. Am J Hum Genet. 1998; 62(3):713-5. PMC: 1376962. DOI: 10.1086/301768. View

Chen L, Sabripour M, Wu E, Prieto V, Fuller G, Frazier M . A mutation-created novel intra-exonic pre-mRNA splice site causes constitutive activation of KIT in human gastrointestinal stromal tumors. Oncogene. 2005; 24(26):4271-80. DOI: 10.1038/sj.onc.1208587. View

Trusolino L, Comoglio P . Scatter-factor and semaphorin receptors: cell signalling for invasive growth. Nat Rev Cancer. 2002; 2(4):289-300. DOI: 10.1038/nrc779. View

Romani M, Tonini G, Banelli B, Allemanni G, Mazzocco K, Scaruffi P . Biological and clinical role of p73 in neuroblastoma. Cancer Lett. 2003; 197(1-2):111-7. DOI: 10.1016/s0304-3835(03)00092-2. View

Caceres J, Stamm S, Helfman D, Krainer A . Regulation of alternative splicing in vivo by overexpression of antagonistic splicing factors. Science. 1994; 265(5179):1706-9. DOI: 10.1126/science.8085156. View

Ni J, Grate L, Donohue J, Preston C, Nobida N, OBrien G . Ultraconserved elements are associated with homeostatic control of splicing regulators by alternative splicing and nonsense-mediated decay. Genes Dev. 2007; 21(6):708-18. PMC: 1820944. DOI: 10.1101/gad.1525507. View

Rossi F, Labourier E, Forne T, Divita G, Derancourt J, Riou J . Specific phosphorylation of SR proteins by mammalian DNA topoisomerase I. Nature. 1996; 381(6577):80-2. DOI: 10.1038/381080a0. View

10.

Hastings M, Krainer A . Pre-mRNA splicing in the new millennium. Curr Opin Cell Biol. 2001; 13(3):302-9. DOI: 10.1016/s0955-0674(00)00212-x. View

11.

Orban T, Olah E . Emerging roles of BRCA1 alternative splicing. Mol Pathol. 2003; 56(4):191-7. PMC: 1187320. DOI: 10.1136/mp.56.4.191. View

12.

Quinn J, Kennedy R, Mullan P, Gilmore P, Carty M, Johnston P . BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. Cancer Res. 2003; 63(19):6221-8. View

13.

Lee J, Gao C, Lee C, Kim M, Vande Woude G . An alternatively spliced form of Met receptor is tumorigenic. Exp Mol Med. 2006; 38(5):565-73. DOI: 10.1038/emm.2006.66. View

14.

Patel N, Kaneko S, Apostolatos H, Bae S, Watson J, Davidowitz K . Molecular and genetic studies imply Akt-mediated signaling promotes protein kinase CbetaII alternative splicing via phosphorylation of serine/arginine-rich splicing factor SRp40. J Biol Chem. 2005; 280(14):14302-9. DOI: 10.1074/jbc.M411485200. View

15.

Zinszner H, Albalat R, Ron D . A novel effector domain from the RNA-binding protein TLS or EWS is required for oncogenic transformation by CHOP. Genes Dev. 1994; 8(21):2513-26. DOI: 10.1101/gad.8.21.2513. View

16.

Naor D, Nedvetzki S, Golan I, Melnik L, Faitelson Y . CD44 in cancer. Crit Rev Clin Lab Sci. 2002; 39(6):527-79. DOI: 10.1080/10408360290795574. View

17.

Dominguez C, Allain F . NMR structure of the three quasi RNA recognition motifs (qRRMs) of human hnRNP F and interaction studies with Bcl-x G-tract RNA: a novel mode of RNA recognition. Nucleic Acids Res. 2006; 34(13):3634-45. PMC: 1540728. DOI: 10.1093/nar/gkl488. View

18.

van Der Houven Van Oordt W, Diaz-Meco M, Lozano J, Krainer A, Moscat J, Caceres J . The MKK(3/6)-p38-signaling cascade alters the subcellular distribution of hnRNP A1 and modulates alternative splicing regulation. J Cell Biol. 2000; 149(2):307-16. PMC: 2175157. DOI: 10.1083/jcb.149.2.307. View

19.

Borjesson P, Postema E, Roos J, Colnot D, Marres H, van Schie M . Phase I therapy study with (186)Re-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with head and neck squamous cell carcinoma. Clin Cancer Res. 2003; 9(10 Pt 2):3961S-72S. View

20.

Karni R, de Stanchina E, Lowe S, Sinha R, Mu D, Krainer A . The gene encoding the splicing factor SF2/ASF is a proto-oncogene. Nat Struct Mol Biol. 2007; 14(3):185-93. PMC: 4595851. DOI: 10.1038/nsmb1209. View